Cerevasc today announced the first-in-human use of its eShunt system to treat medically refractory idiopathic intracranial hypertension (IIH).
Neurotechnology company CranioSense has been awarded approximately $5.5 million in non-dilutive funding through the NIH Blueprint MedTech Program and the U.S. Department of Defense's Joint Warfighter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results